How to appeal a Priority Health amyloidosis (cardiac attr + al) denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Priority Health-specific note: Subsidiary of Corewell Health (Michigan integrated health system, formed from Beaumont + Spectrum 2022); ~1.3M members. Second-largest insurer in Michigan after BCBS Michigan. Michigan DIFS oversight.
What Priority Health typically denies for amyloidosis (cardiac attr + al)
Across Priority Health's commercial and Medicare books, denials cluster around a small number of patterns. For amyloidosis (cardiac attr + al), expect:
- West Michigan narrow-network restrictions
- Step therapy on specialty drugs
- Medicare Advantage Part B drug step therapy
- Behavioral health network adequacy
Treatments most often denied in this category
These are the amyloidosis (cardiac attr + al) treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Vyndaqel / Vyndamax (tafamidis)
- Attruby (acoramidis)
- Amvuttra (vutrisiran) ATTR-CM
- Onpattro (patisiran)
- Wainua (eplontersen)
- D-VCd for AL
How to submit the appeal to Priority Health
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Priority Health cited in the denial.
- File the appeal through Priority Health's portal (members: https://www.priorityhealth.com ; providers: https://www.priorityhealth.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MI, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Frequently asked questions
How long do I have to appeal a Priority Health amyloidosis (cardiac attr + al) denial?
Priority Health allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit a Priority Health appeal?
Members can submit through the Priority Health member portal at https://www.priorityhealth.com. Providers should use the provider portal at https://www.priorityhealth.com/provider. Faxed and mailed appeals are accepted but take longer.
What denials does Priority Health most often issue for amyloidosis (cardiac attr + al)?
Across Priority Health's book of business the common patterns include: West Michigan narrow-network restrictions; Step therapy on specialty drugs; Medicare Advantage Part B drug step therapy. For amyloidosis (cardiac attr + al) specifically, expect denials tied to the FDA-approved indication, step therapy through cheaper alternatives, and prior authorization documentation gaps.
What if Priority Health denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Start your Amyloidosis (cardiac ATTR + AL) appeal
Upload your Priority Health denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com